Cargando…
Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D
OBJECTIVE: To help facilitate economic evaluations of oncology treatments, we mapped responses on cancer-specific instrument to generic preference-based measures. METHODS: Cancer patients (n = 367) completed one cancer-specific instrument, the FACT-G, and two preference-based measures, the EQ-5D and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220776/ https://www.ncbi.nlm.nih.gov/pubmed/24289488 http://dx.doi.org/10.1186/1477-7525-11-203 |
_version_ | 1782342781447962624 |
---|---|
author | Teckle, Paulos McTaggart-Cowan, Helen Van der Hoek, Kim Chia, Stephen Melosky, Barb Gelmon, Karen Peacock, Stuart |
author_facet | Teckle, Paulos McTaggart-Cowan, Helen Van der Hoek, Kim Chia, Stephen Melosky, Barb Gelmon, Karen Peacock, Stuart |
author_sort | Teckle, Paulos |
collection | PubMed |
description | OBJECTIVE: To help facilitate economic evaluations of oncology treatments, we mapped responses on cancer-specific instrument to generic preference-based measures. METHODS: Cancer patients (n = 367) completed one cancer-specific instrument, the FACT-G, and two preference-based measures, the EQ-5D and SF-6D. Responses were randomly divided to form development (n = 184) and cross-validation (n = 183) samples. Relationships between the instruments were estimated using ordinary least squares (OLS), generalized linear models (GLM), and censored least absolute deviations (CLAD) regression approaches. The performance of each model was assessed in terms of how well the responses to the cancer-specific instrument predicted EQ-5D and SF-6D utilities using mean absolute error (MAE) and root mean squared error (RMSE). RESULTS: Physical, functional, and emotional well-being domain scores of the FACT-G best explained the EQ-5D and SF-6D. In terms of accuracy of prediction as measured in RMSE, the CLAD model performed best for the EQ-5D (RMSE = 0.095) whereas the GLM model performed best for the SF-6D (RMSE = 0.061). The GLM predicted SF-6D scores matched the observed values more closely than the CLAD and OLS. CONCLUSION: Our results demonstrate that the estimation of both EQ-5D and SF-6D utility indices using the FACT-G responses can be achieved. The CLAD model for the EQ-5D and the GLM model for the SF-6D are recommended. Thus, it is possible to estimate quality-adjusted life years for economic evaluation from studies where only cancer-specific instrument have been administered. |
format | Online Article Text |
id | pubmed-4220776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42207762014-11-06 Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D Teckle, Paulos McTaggart-Cowan, Helen Van der Hoek, Kim Chia, Stephen Melosky, Barb Gelmon, Karen Peacock, Stuart Health Qual Life Outcomes Research OBJECTIVE: To help facilitate economic evaluations of oncology treatments, we mapped responses on cancer-specific instrument to generic preference-based measures. METHODS: Cancer patients (n = 367) completed one cancer-specific instrument, the FACT-G, and two preference-based measures, the EQ-5D and SF-6D. Responses were randomly divided to form development (n = 184) and cross-validation (n = 183) samples. Relationships between the instruments were estimated using ordinary least squares (OLS), generalized linear models (GLM), and censored least absolute deviations (CLAD) regression approaches. The performance of each model was assessed in terms of how well the responses to the cancer-specific instrument predicted EQ-5D and SF-6D utilities using mean absolute error (MAE) and root mean squared error (RMSE). RESULTS: Physical, functional, and emotional well-being domain scores of the FACT-G best explained the EQ-5D and SF-6D. In terms of accuracy of prediction as measured in RMSE, the CLAD model performed best for the EQ-5D (RMSE = 0.095) whereas the GLM model performed best for the SF-6D (RMSE = 0.061). The GLM predicted SF-6D scores matched the observed values more closely than the CLAD and OLS. CONCLUSION: Our results demonstrate that the estimation of both EQ-5D and SF-6D utility indices using the FACT-G responses can be achieved. The CLAD model for the EQ-5D and the GLM model for the SF-6D are recommended. Thus, it is possible to estimate quality-adjusted life years for economic evaluation from studies where only cancer-specific instrument have been administered. BioMed Central 2013-12-01 /pmc/articles/PMC4220776/ /pubmed/24289488 http://dx.doi.org/10.1186/1477-7525-11-203 Text en Copyright © 2013 Teckle et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Teckle, Paulos McTaggart-Cowan, Helen Van der Hoek, Kim Chia, Stephen Melosky, Barb Gelmon, Karen Peacock, Stuart Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title | Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title_full | Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title_fullStr | Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title_full_unstemmed | Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title_short | Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D |
title_sort | mapping the fact-g cancer-specific quality of life instrument to the eq-5d and sf-6d |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220776/ https://www.ncbi.nlm.nih.gov/pubmed/24289488 http://dx.doi.org/10.1186/1477-7525-11-203 |
work_keys_str_mv | AT tecklepaulos mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT mctaggartcowanhelen mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT vanderhoekkim mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT chiastephen mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT meloskybarb mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT gelmonkaren mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d AT peacockstuart mappingthefactgcancerspecificqualityoflifeinstrumenttotheeq5dandsf6d |